Adding Bevacizumab to Chemo Not Effective for HER2- Inflammatory Breast Cancer

Share this content:
Adding bevacizumab to neoadjuvant and adjuvant chemotherapy did not provide clinical benefit to patients with HER2-negative inflammatory breast cancer.
Adding bevacizumab to neoadjuvant and adjuvant chemotherapy did not provide clinical benefit to patients with HER2-negative inflammatory breast cancer.

Adding bevacizumab to neoadjuvant and adjuvant chemotherapy did not provide clinical benefit to patients with non-metastatic, human epidermal growth factor receptor 2 (HER2)-negative inflammatory breast cancer, a study published in the journal The Lancet Oncology has shown.1

Previous studies have demonstrated that the addition of bevacizumab immunotherapy to standard neoadjuvant chemotherapy improves progression-free survival and pathological complete response rate in patients with HER2-negative metastatic breast cancer; however, it is unclear whether adding bevacizumab to chemotherapy improves outcomes of patients with inflammatory breast cancer.

Therefore, researchers conducted a multicenter, single-arm, phase 2 trial to evaluate the addition of bevacizumab to neoadjuvant and adjuvant chemotherapy in the treatment of patients with HER2-negative non-metastatic inflammatory breast cancer.

For the study, researchers enrolled 100 patients who all received neoadjuvant intravenous fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2, and bevacizumab 15 mg/kg every 3 weeks during cycles 1-4. Patients then received docetaxel 100 mg/m2 and bevacizumab 15 mg/kg during cycles 5-8. Two to 4 weeks after surgery, patients underwent adjuvant radiotherapy, adjuvant bevacizumab, and hormone therapy (if they had a hormone receptor-positive tumor).

Results showed that only 19% (95% CI, 12 - 28) of the 100 patients achieved a pathological complete response after neoadjuvant therapy (P = .16).

In terms of safety, the most frequently reported grade 3-4 treatment-related adverse events during the neoadjuvant phase were neutropenia (89%), febrile neutropenia (37%), and mucositis (23%). During the adjuvant phase, the most common was proteinuria (7% of 75 patients).

Of note, 48% of patients experienced a serious adverse event and 1 patient died of thrombotic microangiopathy due to bevacizumab treatment.

RELATED: Acupuncture With Enhanced Self-care Improves Quality of Life, Reduces Hot Flashes in Breast Cancer

“Longer follow-up and correlative studies to identify patients who might benefit from bevacizumab are needed,” the authors concluded.

Reference

  1. Bertucci F, Fekih M, Autret A, et al. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study [published online ahead of print March 28, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(16)00011-5.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs